News

Dr. Robert M. Califf, U.S. Food and Drug Administration commissioner, and Dr. Robert A. Harrington, the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, sat down for a fireside chat Oct. 15 in Weill Cornell Medicine's Uris Auditorium. 

It may soon be possible to determine which patients with a type of liver cancer called hepatocellular carcinoma would benefit from immunotherapy, according to a preclinical study by Weill Cornell Medicine investigators.

The first randomized, placebo-controlled clinical trial evaluating the impact of therapeutic monoclonal antibodies on the risk of developing long COVID was led by researchers at Weill Cornell Medicine.

How can medicine and public health address unregulated and potentially harmful marijuana products?

Immune cells called monocytes produce a key inflammatory protein called interleukin-1 beta (IL-1β) through an unconventional pathway in patients with systemic lupus erythematosus, commonly referred to as lupus, according to a new study by Weill Cornell Medicine investigators.

Dr. Ali Jalali, an assistant professor of population health sciences at Weill Cornell Medicine, was awarded the prestigious National Institutes of Health Director’s New Innovator Award through its Helping to End Addiction Long-term (HEAL) Initiative.

A new technology enables the control of specific brain circuits non-invasively with magnetic fields, according to a preclinical study from researchers at Weill Cornell Medicine, The Rockefeller University and the Icahn School of Medicine at Mount Sinai. 

How bladder cancer originates and progresses has been illuminated as never before in a study led by researchers at Weill Cornell Medicine and the New York Genome Center. 

Dr. Randy Longman, director of the Jill Roberts Center for Inflammatory Bowel Disease and an associate professor of medicine at Weill Cornell Medicine, and colleagues have received the NIH Director’s Transformative Research Award to develop the tools needed to understand how the gut microbiome drives metabolic pathways.

Researchers at Weill Cornell Medicine have developed breast cancer cell-of-origin signatures that can better predict both overall and progression-free survival of patients with breast cancer compared to previously developed genomic signatures.

Researchers have found that removing protected class regulation from Medicare prescription drug policies could greatly reduce the United States' prescription drug spending—this could have saved potentially $47 billion between 2011-2019.

The possibility of parental disclosure through online patient portals led older adolescents to hesitate in sharing complete health information with doctors, putting them at risk of missed diagnoses and treatments.

Dr. Alessandro Fichera, a prominent colorectal surgeon, has been named chief of the Division of Colorectal Surgery at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, effective Oct. 14. 

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to less invasiveness and weaker biological activity, according to a multicenter study conducted at Weill Cornell Medicine, Memorial Sloan Kettering, and other institutions.

The award honors the institutions for their commitment to the personal wellness and resilience of their emergency medicine department staff.

Awards, honors and achievements for the month of September.

Weill Cornell Medicine investigators have found that two genetic variants that confer high risk of Alzheimer’s disease (AD) together trigger a harmful inflammatory response in the brain’s immune cells, particularly in females, in a preclinical model.

A ribbon-cutting ceremony celebrates the opening of a new pediatric sub-specialty practice at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center.

Stimulating a key metabolic pathway in T cells can make them work more effectively against tumors when combined with immune checkpoint inhibitor therapy, according to a preclinical study led by researchers at Weill Cornell Medicine.

Weill Cornell Medicine was awarded a $4.2 million Program Project Grant renewal from the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID). This will fund the development of a vaccine that can prevent the cytomegalovirus (CMV) from being transmitted from mother to baby during pregnancy.